UNASSIGNED: AP9-cd, a novel @entity24829 composition from @entity51035 has significant anticancer potential, and to further enhance its activity, it was lucratively encumbered into solid lipid nanoparticles (SLNs). These nanoparticles were formulated by micro-emulsion technique with 70% drug trap competence. AP9-cd-SLNs were regular, solid, globular particles in the range of 100-200  nm, which were confirmed by electron microscopic studies. Moreover, AP9-cd-SLNs were found to be stable for up to six months in terms of color, particle size, zeta potential, drug content and entrapment. AP9-cd-SLNs have 30-50% higher cytotoxic and apoptotic potential than the AP9-cd alone. The augmented anticancer potential of AP9-cd-SLNs was observed in cytotoxic IC50 value, apoptosis signaling cascade and in @entity8270 ( @entity8270 ) model. AP9-cd-SLNs induce apoptosis in Molt-4 cells via both intrinsic and extrinsic pathway. Moreover, the dummy nanoparticles (SLNs without AP9-cd) did not have any cytotoxic effect in @entity5 as well as in normal cells. Consequently, SLNs of AP9-cd significantly augment the apoptotic and antitumor potential of AP9-cd. The present study provides a podium for ornamental the remedial latent via novel delivery systems like solid lipid nanoparticles.

The augmented anticancer potential of AP9-cd loaded solid lipid nanoparticles in human leukemia Molt-4 cells and experimental XXXX .

@entity24829 :: ('CHEBI:25036', 'Chemical') :: ['lignan'] @entity51035 :: ('3322', 'Species') :: ['Cedrus deodara'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity8270 :: ('MESH:D002286', 'Disease') :: ['EAT', 'Ehrlich ascites tumor']
@entity5 :: (MESH:D009369,Disease) :: ['tumor']
